PFE
Pfizer Inc.
Stock$24.27
$-0.02 (-0.08%)
Current Price (API): $24.27About
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
Price History (Last 30 Days)
Latest News & Updates
Pfizer faces mounting challenges including a failed phase 3 clinical trial for c...
Pfizer faces mounting challenges including a failed phase 3 clinical trial for cancer drug sigvotatug vedotin and the departure of CFO Dave Denton. Despite these setbacks and the $43 billion Seagen acquisition, the article argues the stock remains attractive due to strong pipeline candidates like MET-097i in weight loss, successful products like Padcev and Abrysvo, and a solid 7.3% dividend yield.
Pfizer offers a compelling 6.9% dividend yield, significantly higher than the S&...
Pfizer offers a compelling 6.9% dividend yield, significantly higher than the S&P 500's 1% yield, making it attractive for income investors despite being deeply out of favor on Wall Street. The stock has fallen 60% from its 2021 peak due to disappointing COVID vaccine sales and struggles in drug development, particularly missing out on the lucrative GLP-1 weight-loss drug category. However, the author argues that Pfizer's challenges are typical industry dynamics and the company's strong history suggests it will recover, making it a potential opportunity for long-term investors willing to tolerate near-term uncertainty.
RBC analyst Trung Huynh declared Eli Lilly the 'clear winner' at the American Di...
RBC analyst Trung Huynh declared Eli Lilly the 'clear winner' at the American Diabetes Association conference, citing positive trial data for retatrutide and Foundayo. However, Novo Nordisk's chief science officer Martin Holst Lange argues the competition is far from over, noting that tolerability and effectiveness against comorbidities will play important roles. Eli Lilly reported 56% revenue growth last quarter, while Novo Nordisk experienced negative adjusted sales growth, creating a significant valuation gap between the two companies.
Oblenio Bio announced the closing of a $62 million Series B financing round led...
Oblenio Bio announced the closing of a $62 million Series B financing round led by Pfizer Ventures, with participation from Deep Track Capital, GV, and Aditum Bio. The funds will support clinical development of LBL-051, a tri-specific T-cell engager designed to achieve immune system reset for autoimmune diseases. Recent preclinical data presented at EULAR 2026 demonstrated the program's ability to safely deplete B-cells and plasma cells without causing cytokine release syndrome, with the company planning to initiate first-in-human trials this year.
The article recommends Pfizer and Medtronic as attractive dividend stocks for lo...
The article recommends Pfizer and Medtronic as attractive dividend stocks for long-term investors seeking portfolio stability amid economic uncertainties. Despite recent challenges, both healthcare leaders offer compelling dividend yields (6.8% and 3.6% respectively) and have strong pipelines and growth opportunities that could drive returns over the next decade.
Pfizer stock has declined over 50% from its 2021 peak, driving its dividend yiel...
Pfizer stock has declined over 50% from its 2021 peak, driving its dividend yield to 6.8%. While the company faces near-term headwinds from patent expirations on key drugs and lacks immediate replacements, analysts suggest long-term investors should view this as a turnaround opportunity. With a century-long track record and several drug trials scheduled for 2026, Pfizer is expected to navigate this difficult period and return to growth, potentially offering both income and capital appreciation.
Retiring on $500,000 is possible with the right strategy. The article recommends...
Retiring on $500,000 is possible with the right strategy. The article recommends three high-dividend income stocks that could help achieve this goal: Ares Capital (10.6% yield), Energy Transfer (7.2% yield), and Pfizer (6.8% yield). Combined with Social Security benefits, these stocks could generate sufficient income for retirement, though diversification beyond three stocks is essential.
Eli Lilly is thriving in the GLP-1 weight-loss drug market with strong sales gro...
Eli Lilly is thriving in the GLP-1 weight-loss drug market with strong sales growth, but offers minimal dividend yield of 0.6%. Pfizer, struggling with patent expirations and GLP-1 setbacks, offers a much higher 6.6% dividend yield. While Pfizer faces near-term headwinds, income-focused investors willing to accept risk may find value in its substantial dividend, though the payout ratio exceeding 100% raises concerns.
Pfizer stock fell 2.74% following the announcement that CFO Dave Denton will dep...
Pfizer stock fell 2.74% following the announcement that CFO Dave Denton will depart in August, raising investor concerns about leadership continuity and the company's ability to meet 2026 guidance. While recent drug approvals strengthen the pipeline, the CFO transition creates uncertainty around financial execution and earnings recovery.
The FDA approved an expanded indication for Merck's Capvaxive pneumococcal vacci...
The FDA approved an expanded indication for Merck's Capvaxive pneumococcal vaccine, extending its use to children and adolescents ages 2-17 with chronic conditions. The approval was based on Phase 3 STRIDE-13 trial data and makes Capvaxive the only pneumococcal conjugate vaccine specifically studied and indicated for this patient group in the U.S. The vaccine covers serotypes associated with approximately 79% of invasive pneumococcal disease cases among at-risk children.
